Skip to main content
Top
Published in: Abdominal Radiology 2/2013

01-04-2013

Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens

Authors: Shota Tatsumoto, Yoshihisa Kodama, Yasuo Sakurai, Toshiya Shinohara, Akio Katanuma, Hiroyuki Maguchi

Published in: Abdominal Radiology | Issue 2/2013

Login to get access

Abstract

Purpose

To retrospectively determine whether enhancement patterns in the pancreatic and equilibrium phases of computed tomography (CT) for pancreatic neuroendocrine neoplasms are related to prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens.

Methods

Twenty-five pancreatic neuroendocrine neoplasms in 22 patients underwent preoperative dynamic CT. Tumors were classified into two groups by enhancement patterns on preoperative CT. A washout pattern was defined as peak enhancement in the pancreatic phase with washout of at least 60 Hounsfield units in the equilibrium phase. Group 1 comprised tumors showing a washout pattern in more than half of tumor and Group 2 comprised tumors showing a washout pattern in less than half of the tumor. The Ki-67 index and the presence of vascular invasion were evaluated in surgical specimens. The Ki-67 index from biopsy specimens was compared with that from surgical specimens.

Results

There were 12 surgical specimens in Group 1 and 13 in Group 2. Group 2 showed significant correlations with larger Ki-67 indices (p < 0.05) and positive vascular invasion (p < 0.05). The Ki-67 index discrepancy between biopsy and surgical specimens of Group 2 was significantly greater than that of Group 1 (p < 0.05).

Conclusions

Pancreatic neuroendocrine neoplasms in which less than half of the tumor showed a washout pattern were correlated with poor prognostic factors. Analysis of enhancement patterns may provide predictive information about whether endoscopic ultrasound-guided fine-needle aspiration biopsy is reliable for the assessment of Ki-67 index.
Literature
1.
go back to reference Klimstra DS, Capella C, Arnold R (2010) Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al. (eds) WHO Classification of Tumours of the Digestive System, 4th edn. Lyon, France: IARC Press, pp 322–326 Klimstra DS, Capella C, Arnold R (2010) Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al. (eds) WHO Classification of Tumours of the Digestive System, 4th edn. Lyon, France: IARC Press, pp 322–326
2.
go back to reference Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. (2004) Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28:1145–1153PubMedCrossRef Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. (2004) Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28:1145–1153PubMedCrossRef
3.
go back to reference Schmitt AM, Anlauf M, Rousson V, et al. (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31:1677–1682PubMedCrossRef Schmitt AM, Anlauf M, Rousson V, et al. (2007) WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 31:1677–1682PubMedCrossRef
4.
go back to reference Horton KM, Hruban RH, Yeo C, Fishman EK (2006) Multi-detector row CT of pancreatic islet cell tumors. Radiographics 26:453–464PubMedCrossRef Horton KM, Hruban RH, Yeo C, Fishman EK (2006) Multi-detector row CT of pancreatic islet cell tumors. Radiographics 26:453–464PubMedCrossRef
5.
go back to reference Rha SE, Jung SE, Lee KH, et al. (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62:371–377PubMedCrossRef Rha SE, Jung SE, Lee KH, et al. (2007) CT and MR imaging findings of endocrine tumor of the pancreas according to WHO classification. Eur J Radiol 62:371–377PubMedCrossRef
6.
go back to reference Lewis RB, Lattin GE Jr, Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464PubMedCrossRef Lewis RB, Lattin GE Jr, Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464PubMedCrossRef
7.
go back to reference Hayashi D, Tkacz JN, Hammond S, et al. (2011) Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation. Jpn J Radiol 29:85–91PubMedCrossRef Hayashi D, Tkacz JN, Hammond S, et al. (2011) Gastroenteropancreatic neuroendocrine tumors: multimodality imaging features with pathological correlation. Jpn J Radiol 29:85–91PubMedCrossRef
8.
go back to reference Ichikawa T, Peterson MS, Federle MP, et al. (2000) Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 216:163–171PubMed Ichikawa T, Peterson MS, Federle MP, et al. (2000) Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 216:163–171PubMed
9.
go back to reference Rodallec M, Vilgrain V, Couvelard A, et al. (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85PubMedCrossRef Rodallec M, Vilgrain V, Couvelard A, et al. (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85PubMedCrossRef
10.
go back to reference d’Assignies G, Couvelard A, Bahrami S, et al. (2009) Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250:407–416PubMedCrossRef d’Assignies G, Couvelard A, Bahrami S, et al. (2009) Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. Radiology 250:407–416PubMedCrossRef
11.
go back to reference Hattori Y, Gabata T, Matsui O, et al. (2009) Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol 15:3114–3121PubMedCrossRef Hattori Y, Gabata T, Matsui O, et al. (2009) Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis. World J Gastroenterol 15:3114–3121PubMedCrossRef
12.
go back to reference La Rosa S, Klersy C, Uccella S, et al. (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40:30–40PubMedCrossRef La Rosa S, Klersy C, Uccella S, et al. (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40:30–40PubMedCrossRef
13.
go back to reference Rindi G, Klöppel G, Couvelard A, et al. (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762PubMedCrossRef Rindi G, Klöppel G, Couvelard A, et al. (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762PubMedCrossRef
14.
go back to reference Herwick S, Miller FH, Keppke AL (2006) MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 187:W472–W480PubMedCrossRef Herwick S, Miller FH, Keppke AL (2006) MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 187:W472–W480PubMedCrossRef
15.
go back to reference Micke P, Ostman A (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217–1233PubMedCrossRef Micke P, Ostman A (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217–1233PubMedCrossRef
16.
go back to reference Hwang RF, Moore T, Arumugam T, et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68:918–926PubMedCrossRef Hwang RF, Moore T, Arumugam T, et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 68:918–926PubMedCrossRef
17.
go back to reference Aranha GV, Georgen R (1989) Gastric linitis plastica is not a surgical disease. Surgery 106:758–762PubMed Aranha GV, Georgen R (1989) Gastric linitis plastica is not a surgical disease. Surgery 106:758–762PubMed
18.
go back to reference Amorn Y, Knight WA Jr (1978) Primary linitis plastica of the colon: report of two cases and review of the literature. Cancer 41:2420–2425PubMedCrossRef Amorn Y, Knight WA Jr (1978) Primary linitis plastica of the colon: report of two cases and review of the literature. Cancer 41:2420–2425PubMedCrossRef
19.
go back to reference Dawson PJ, Karrison T, Ferguson DJ (1986) Histologic features associated with long-term survival in breast cancer. Hum Pathol 17:1015–1021PubMedCrossRef Dawson PJ, Karrison T, Ferguson DJ (1986) Histologic features associated with long-term survival in breast cancer. Hum Pathol 17:1015–1021PubMedCrossRef
20.
go back to reference Asayama Y, Yoshimitsu K, Irie H, et al. (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155PubMedCrossRef Asayama Y, Yoshimitsu K, Irie H, et al. (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155PubMedCrossRef
21.
go back to reference Marion-Audibert AM, Barel C, Gouysse G, et al. (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125:1094–1104PubMedCrossRef Marion-Audibert AM, Barel C, Gouysse G, et al. (2003) Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 125:1094–1104PubMedCrossRef
22.
go back to reference Couvelard A, O’Toole D, Turley H, et al. (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94–101PubMedCrossRef Couvelard A, O’Toole D, Turley H, et al. (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94–101PubMedCrossRef
23.
go back to reference Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al. (2007) Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 13:187–196PubMedCrossRef Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al. (2007) Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 13:187–196PubMedCrossRef
24.
go back to reference Ekeblad S, Skogseid B, Dunder K, et al. (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798–7803PubMedCrossRef Ekeblad S, Skogseid B, Dunder K, et al. (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798–7803PubMedCrossRef
25.
go back to reference Pape UF, Jann H, Müller-Nordhorn J, et al. (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265PubMedCrossRef Pape UF, Jann H, Müller-Nordhorn J, et al. (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265PubMedCrossRef
26.
go back to reference Strosberg J, Nasir A, Coppola D, Wick M, Kvols L (2009) Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 40:1262–1268PubMedCrossRef Strosberg J, Nasir A, Coppola D, Wick M, Kvols L (2009) Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 40:1262–1268PubMedCrossRef
27.
go back to reference Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35:853–860PubMedCrossRef Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35:853–860PubMedCrossRef
28.
go back to reference Figueiredo FA, Giovannini M, Monges G, et al. (2009) EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endoscopy 70:907–914CrossRef Figueiredo FA, Giovannini M, Monges G, et al. (2009) EUS-FNA predicts 5-year survival in pancreatic endocrine tumors. Gastrointest Endoscopy 70:907–914CrossRef
Metadata
Title
Pancreatic neuroendocrine neoplasm: correlation between computed tomography enhancement patterns and prognostic factors of surgical and endoscopic ultrasound-guided fine-needle aspiration biopsy specimens
Authors
Shota Tatsumoto
Yoshihisa Kodama
Yasuo Sakurai
Toshiya Shinohara
Akio Katanuma
Hiroyuki Maguchi
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9953-8

Other articles of this Issue 2/2013

Abdominal Radiology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine